An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology

Interpretation of mixed models and marginal models with cohort attrition due to death and drop-out

(2017) Anaïs Rouanet et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements

(2017) Chien-Ju Lin et al.   STATISTICS IN MEDICINE

Biased and unbiased estimation in longitudinal studies with informative visit processes

(2016) Charles E. McCulloch et al.   BIOMETRICS

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab

(2016) Cong Zhou et al.   BRITISH JOURNAL OF CANCER

Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience

(2016) Han Hsi Wong et al.   EUROPEAN JOURNAL OF CANCER

A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials

(2016) Yong Zang et al.   STATISTICS IN MEDICINE

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function

(2015) Wai Yin Yeung et al.   PHARMACEUTICAL STATISTICS

A review of statistical designs for improving the efficiency of phase II studies in oncology

(2015) James MS Wason et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Adaptive designs for identifying optimal biological dose for molecularly targeted agents

(2014) Yong Zang et al.   Clinical Trials

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

(2014) Sophie Postel-Vinay et al.   EUROPEAN JOURNAL OF CANCER

Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents

(2014) Nolan A. Wages et al.   Journal of Biopharmaceutical Statistics

Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes

(2014) Ick Hoon Jin et al.   JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

Joint modelling of repeated measurements and time-to-event outcomes: flexible model specification and exact likelihood inference

(2014) Jessica Barrett et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY

A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy

(2014) Karen Sinclair et al.   STATISTICS IN MEDICINE

A Bayesian adaptive Phase I–II clinical trial for evaluating efficacy and toxicity with delayed outcomes

(2013) Joseph S Koopmeiners et al.   Clinical Trials

A Bayesian dose finding design for oncology clinical trials of combinational biological agents

(2013) Chunyan Cai et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS

Designing exploratory cancer trials using change in tumour size as primary endpoint

(2012) Thomas Jaki et al.   STATISTICS IN MEDICINE

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

(2011) Sophie Postel-Vinay et al.   JOURNAL OF CLINICAL ONCOLOGY

An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials

(2011) Akihiro Hirakawa   STATISTICS IN MEDICINE

Flexible univariate and multivariate models based on hidden truncation

(2009) Barry C. Arnold   JOURNAL OF STATISTICAL PLANNING AND INFERENCE

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes

(2009) Ying Yuan et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS